Fuzhou Dongze Medical Device get funded to gain a position in China’s hemodialysis market

   Date:2013/11/19     Source:

Shanghai Bluesail Investment Co. offered to fund RMB 30 million to Fuzhou Dongze Medical Device Co. and hold its 30% share.

Fuzhou Dongze’s primary focus in on Kidney substitute treatment, man-made kidney treatment and in-depth hemodialysis treatment. In 2013, the company expects to reach RMB 33 million of revenue and RMB 4.2 million of net profit. With the funds provided, Dongze Medical plans to win a portion of China’s hemodialysis market by offering innovative hemodialysis product range and clinical treatment service. 

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号